Guangdong Dtech Technology (01377) plans to use idle funds for cash management.

21:41 19/08/2026

Ding Tai Technology (01377) announced that the company will hold the third meeting of the Audit Committee of the second Board of Directors and the twentieth meeting of the second Board of Directors on August 19, 2026. The agenda includes the review and approval of the proposal regarding the use of idle self-owned funds for cash management. The company (including subsidiaries) is permitted to use idle self-owned funds for cash management, not exceeding RMB 1.5 billion (inclusive) on the condition that it does not affect normal operations and ensures fund liquidity and security. This amount can be used within 12 months from the date of approval by the shareholders' meeting, and within the above-mentioned limit and its validity period, funds may be used in a rolling manner.

Guangdong Dtech Technology (01377) announced that on August 19, 2026, the company will hold the third meeting of the Audit Committee of the Second Board of Directors and the twentieth meeting of the Second Board of Directors to review and approve the proposal on the use of idle self-owned funds for cash management. The company (including subsidiaries) is authorized to use idle self-owned funds for cash management, not exceeding 1.5 billion RMB (inclusive) under the premise of not affecting normal operations and ensuring the liquidity and safety of funds. This amount can be used within 12 months from the date of approval by the shareholders' meeting, and within the above amount and its validity period, funds can be used in a rolling manner.

A-shares Evening Hotspots | Cancer Vaccine Achieves Milestone Breakthrough! Moderna Soared 150% at One Point, U.S. Pharmaceutical Stocks Explode Collectively

CMOC Group Limited (03993) announced its interim results, with a net profit attributable to shareholders of approximately 16.152 billion yuan, representing a year-on-year increase of 86.27%. A dividend of 0.95 yuan is proposed for every 10 shares.

SICC Co., Ltd. (02631) reported a 15.1% year-on-year growth in mid-term operating revenue to 914 million yuan, focusing on ramping up large-sized products and driving the continuous optimization and upgrade of product structure.

A-shares Evening Hotspots | Cancer Vaccine Achieves Milestone Breakthrough! Moderna Soared 150% at One Point, U.S. Pharmaceutical Stocks Explode Collectively